{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-21-057374","form_type":"8-K","ticker":"STRO","cik":"0001382101","company_name":"SUTRO BIOPHARMA, INC.","filed_at":"2021-11-17T23:59:59+00:00","discovered_at":"2026-05-14T18:04:12.300348+00:00","generated_at":"2026-06-28T07:19:13.296526+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"confidence":"high","headline":"Sutro Biopharma appoints Heidi Hunter as Class I director, effective Nov 19, 2021","bullets":["Heidi Hunter appointed Class I director and member of Audit and Science & Technology Committees.","Receives pro rata annual retainers: $40K director, $10K audit, $5K science/tech.","Granted option for 24,000 shares vesting monthly over three years; 9,884 shares vesting until 2022 annual meeting.","Exercise price equals closing price on Nov 19, 2021."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-21-057374","json":"https://secwatch.observer/filing/0001564590-21-057374.json","markdown":"https://secwatch.observer/filing/0001564590-21-057374.md","text":"https://secwatch.observer/filing/0001564590-21-057374.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1382101/000156459021057374/0001564590-21-057374-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1382101/000156459021057374/stro-8k_20211112.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T07:19:13.296526+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ef808f71ae","claim":"Heidi Hunter was appointed as Class I director at SUTRO BIOPHARMA, INC..","evidence_excerpt":"On November 12, 2021, the board of directors (the “ Board ”) of Sutro Biopharma, Inc. (the “ Company ”) appointed Heidi Hunter, as a Class I director and member of the Audit Committee and Science and Technology Committee, effective as of November 19, 2021.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1382101/000156459021057374/0001564590-21-057374-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class I director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}